PURPOSE: 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT), a cell proliferation positron emission tomography (PET) tracer, has been shown in numerous tumors to be more specific than 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) but less sensitive. We studied the capacity of a nontoxic concentration of 5-fluoro-2'-deoxyuridine (FdUrd), a thymidine synthesis inhibitor, to increase uptake of [(18)F]FLT in tumor xenografts. METHODS: The duration of the FdUrd effect in vivo on tumor cell cycling and thymidine analogue uptake was studied by varying FdUrd pretreatment timing and holding constant the timing of subsequent flow cytometry and 5-[(125)I]iodo-2'-deoxyuridine biodistribution measurements. In [(18)F]FLT studies, FdUrd pretreatment was generally performed 1 h before radiotracer injection. [(18)F]FLT biodistributions were measured 1 to 3 h after radiotracer injection of mice grafted with five different human tumors and pretreated or not with FdUrd and compared with [(18)F]FDG tumor uptake. Using microPET, the dynamic distribution of [(18)F]FLT was followed for 1.5 h in FdUrd pretreated mice. High-field T2-weighted magnetic resonance imaging (MRI) and histology were used comparatively in assessing tumor viability and proliferation. RESULTS: FdUrd induced an immediate increase in tumor uptake of 5-[(125)I]iodo-2'-deoxyuridine, that vanished after 6 h, as also confirmed by flow cytometry. Biodistribution measurements showed that FdUrd pretreatment increased [(18)F]FLT uptake in all tumors by factors of 3.2 to 7.8 compared with controls, while [(18)F]FDG tumor uptake was about fourfold and sixfold lower in breast cancers and lymphoma. Dynamic PET in FdUrd pretreated mice showed that [(18)F]FLT uptake in all tumors increased steadily up to 1.5 h. MRI showed a well-vascularized homogenous lymphoma with high [(18)F]FLT uptake, while in breast cancer, a central necrosis shown by MRI was inactive in PET, consistent with the histomorphological analysis. CONCLUSION: We showed a reliable and significant uptake increase of [(18)F]FLT in different tumor xenografts after low-dose FdUrd pretreatment. These results show promise for a clinical application of FdUrd aimed at increasing the sensitivity of [(18)F]FLT PET.
PURPOSE: 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT), a cell proliferation positron emission tomography (PET) tracer, has been shown in numerous tumors to be more specific than 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) but less sensitive. We studied the capacity of a nontoxic concentration of 5-fluoro-2'-deoxyuridine (FdUrd), a thymidine synthesis inhibitor, to increase uptake of [(18)F]FLT in tumor xenografts. METHODS: The duration of the FdUrd effect in vivo on tumor cell cycling and thymidine analogue uptake was studied by varying FdUrd pretreatment timing and holding constant the timing of subsequent flow cytometry and 5-[(125)I]iodo-2'-deoxyuridine biodistribution measurements. In [(18)F]FLT studies, FdUrd pretreatment was generally performed 1 h before radiotracer injection. [(18)F]FLT biodistributions were measured 1 to 3 h after radiotracer injection of mice grafted with five different humantumors and pretreated or not with FdUrd and compared with [(18)F]FDG tumor uptake. Using microPET, the dynamic distribution of [(18)F]FLT was followed for 1.5 h in FdUrd pretreated mice. High-field T2-weighted magnetic resonance imaging (MRI) and histology were used comparatively in assessing tumor viability and proliferation. RESULTS:FdUrd induced an immediate increase in tumor uptake of 5-[(125)I]iodo-2'-deoxyuridine, that vanished after 6 h, as also confirmed by flow cytometry. Biodistribution measurements showed that FdUrd pretreatment increased [(18)F]FLT uptake in all tumors by factors of 3.2 to 7.8 compared with controls, while [(18)F]FDG tumor uptake was about fourfold and sixfold lower in breast cancers and lymphoma. Dynamic PET in FdUrd pretreated mice showed that [(18)F]FLT uptake in all tumors increased steadily up to 1.5 h. MRI showed a well-vascularized homogenous lymphoma with high [(18)F]FLT uptake, while in breast cancer, a central necrosis shown by MRI was inactive in PET, consistent with the histomorphological analysis. CONCLUSION: We showed a reliable and significant uptake increase of [(18)F]FLT in different tumor xenografts after low-dose FdUrd pretreatment. These results show promise for a clinical application of FdUrd aimed at increasing the sensitivity of [(18)F]FLT PET.
Authors: Y M Dupertuis; M Vazquez; J P Mach; N De Tribolet; C Pichard; D O Slosman; F Buchegger Journal: Cancer Res Date: 2001-11-01 Impact factor: 12.701
Authors: Yves M Dupertuis; Wei-Hong Xiao; Nicolas De Tribolet; Claude Pichard; Daniel O Slosman; Angelika Bischof Delaloye; Franz Buchegger Journal: Eur J Nucl Med Mol Imaging Date: 2002-02-02 Impact factor: 9.236
Authors: L B Been; P H Elsinga; J de Vries; D C P Cobben; P L Jager; H J Hoekstra; A J H Suurmeijer Journal: Eur J Surg Oncol Date: 2005-11-02 Impact factor: 4.424
Authors: Sarah Everitt; Rodney J Hicks; David Ball; Tomas Kron; Michal Schneider-Kolsky; Tania Walter; David Binns; Michael Mac Manus Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-20 Impact factor: 7.038
Authors: L Leichman; H Silberman; C G Leichman; C P Spears; M Ray; F M Muggia; M Kiyabu; R Radin; L Laine; S Stain Journal: J Clin Oncol Date: 1992-12 Impact factor: 44.544
Authors: Laura Kenny; R Charles Coombes; David M Vigushin; Adil Al-Nahhas; Sami Shousha; Eric O Aboagye Journal: Eur J Nucl Med Mol Imaging Date: 2007-03-02 Impact factor: 9.236
Authors: Joseph J Grudzinski; John M Floberg; Sarah R Mudd; Justin J Jeffery; Eric T Peterson; Alice Nomura; Ronald R Burnette; Wolfgang A Tomé; Jamey P Weichert; Robert Jeraj Journal: Phys Med Biol Date: 2012-03-07 Impact factor: 3.609
Authors: Richa Gandhi; Christopher Cawthorne; Lucinda J L Craggs; John D Wright; Juozas Domarkas; Ping He; Joanna Koch-Paszkowski; Michael Shires; Andrew F Scarsbrook; Stephen J Archibald; Charalampos Tsoumpas; Marc A Bailey Journal: J Nucl Cardiol Date: 2019-11-18 Impact factor: 5.952
Authors: Peter J O'Brien; Michelle Lee; Mary E Spilker; Cathy C Zhang; Zhengming Yan; Timothy C Nichols; Wenlin Li; Caroline H Johnson; Gary J Patti; Gary Siuzdak Journal: Cancer Metab Date: 2013-01-23